348 related articles for article (PubMed ID: 28248020)
1. [Anogenital warts: a new way of solving the common problem of urology (results of long-term follow-up)].
Protasov AD; Lipatov IS; Kostinov MP; Tezikov YV; Shmitko AD; Pakhomov DV; Blagovidov DA; Zhestkov AV; Ryzhov AA; Vekhova EV
Urologiia; 2016 Nov; (5):47-51. PubMed ID: 28248020
[TBL] [Abstract][Full Text] [Related]
2. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.
Edwards L; Ferenczy A; Eron L; Baker D; Owens ML; Fox TL; Hougham AJ; Schmitt KA
Arch Dermatol; 1998 Jan; 134(1):25-30. PubMed ID: 9449906
[TBL] [Abstract][Full Text] [Related]
3. Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT.
Gilson R; Nugent D; Bennett K; Doré CJ; Murray ML; Meadows J; Haddow LJ; Lacey C; Sandmann F; Jit M; Soldan K; Tetlow M; Caverly E; Nathan M; Copas AJ
Health Technol Assess; 2020 Sep; 24(47):1-86. PubMed ID: 32975189
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac trial).
Murray ML; Meadows J; Doré CJ; Copas AJ; Haddow LJ; Lacey C; Jit M; Soldan K; Bennett K; Tetlow M; Nathan M; Gilson R
BMC Med Res Methodol; 2018 Nov; 18(1):125. PubMed ID: 30400777
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
Goldstone SE; Giuliano AR; Palefsky JM; Lazcano-Ponce E; Penny ME; Cabello RE; Moreira ED; Baraldi E; Jessen H; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Bautista O; Das R; Group T; Luxembourg A; Zhou HJ; Saah A
Lancet Infect Dis; 2022 Mar; 22(3):413-425. PubMed ID: 34780705
[TBL] [Abstract][Full Text] [Related]
6. Imiquimod 5% cream for external genital or perianal warts in human immunodeficiency virus-positive patients treated with highly active antiretroviral therapy: an open-label, noncomparative study.
Saiag P; Bauhofer A; Bouscarat F; Aquilina C; Ortonne JP; Dupin N; Mougin C
Br J Dermatol; 2009 Oct; 161(4):904-9. PubMed ID: 19466962
[TBL] [Abstract][Full Text] [Related]
7. Management of female genital warts with an analog of imiquimod 2% in cream: a randomized, double-blind, placebo-controlled study.
Syed TA; Ahmadpour OA; Ahmad SA; Ahmad SH
J Dermatol; 1998 Jul; 25(7):429-33. PubMed ID: 9714974
[TBL] [Abstract][Full Text] [Related]
8. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus (HPV) viral load and HPV type in the clinical outcome of HIV-positive patients treated with imiquimod for anogenital warts and anal intraepithelial neoplasia.
Sanclemente G; Herrera S; Tyring SK; Rady PL; Zuleta JJ; Correa LA; He Q; Wolff JC
J Eur Acad Dermatol Venereol; 2007 Sep; 21(8):1054-60. PubMed ID: 17714124
[TBL] [Abstract][Full Text] [Related]
10. [Topical imiquimod cream in the treatment of external anogenital warts: personal experience].
Senatori R; Dionisi B; Lippa P; Inghirami P
Minerva Ginecol; 2003 Dec; 55(6):541-6. PubMed ID: 14676745
[TBL] [Abstract][Full Text] [Related]
11. Update on the treatment of genital warts.
Scheinfeld N
Dermatol Online J; 2013 Jun; 19(6):18559. PubMed ID: 24011309
[TBL] [Abstract][Full Text] [Related]
12. Treatment of genital warts with an immune-response modifier (imiquimod).
Beutner KR; Spruance SL; Hougham AJ; Fox TL; Owens ML; Douglas JM
J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):230-9. PubMed ID: 9486679
[TBL] [Abstract][Full Text] [Related]
13. [A model-based comparison of cost effectiveness of imiquimod versus podophyllotoxin for the treatment of external anogenital warts in France].
Lafuma A; Monsonego J; Moyal-Barracco M; Pribil C
Ann Dermatol Venereol; 2003; 130(8-9 Pt 1):731-6. PubMed ID: 14576602
[TBL] [Abstract][Full Text] [Related]
14. Extensive condyloma acuminata treated with imiquimod 5% cream: a case report.
Cox JT
Clin Exp Dermatol; 2003 Nov; 28 Suppl 1():51-4. PubMed ID: 14616817
[TBL] [Abstract][Full Text] [Related]
15. Human Papillomavirus and Genital Warts: A Review of the Evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines.
Park IU; Introcaso C; Dunne EF
Clin Infect Dis; 2015 Dec; 61 Suppl 8():S849-55. PubMed ID: 26602622
[TBL] [Abstract][Full Text] [Related]
16. [External genital warts (condylomata)].
Bouscarat F; Pelletier F; Fouéré S; Janier M; Bertolloti A; Aubin F;
Ann Dermatol Venereol; 2016 Nov; 143(11):741-745. PubMed ID: 27773506
[No Abstract] [Full Text] [Related]
17. [Mechanisms of imiquimod indirect antiviral activity].
Hober D; Ajram L; Chehadeh W; Lazrek M; Goffard A; Dewilde A; Wattré P
Ann Biol Clin (Paris); 2005; 63(2):155-63. PubMed ID: 15771973
[TBL] [Abstract][Full Text] [Related]
18. Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in external anogenital warts.
Schöfer H; Van Ophoven A; Henke U; Lenz T; Eul A
Eur J Dermatol; 2006; 16(6):642-8. PubMed ID: 17229604
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and safety of 5% imiquimod cream in external genital warts: a 6 month follow-up evaluation].
Vexiau D; Decuypère L; Moyse D; Aractingi S
Ann Dermatol Venereol; 2005 Nov; 132(11 Pt 1):845-51. PubMed ID: 16327713
[TBL] [Abstract][Full Text] [Related]
20. Intralesional injection of Mycobacterium w vaccine vs imiquimod, 5%, cream in patients with anogenital warts: a randomized clinical trial.
Kumar P; Dar L; Saldiwal S; Varma S; Datt Upadhyay A; Talwar D; Sharma VK; Verma KK; Dwivedi SN; Raj R; Gupta S
JAMA Dermatol; 2014 Oct; 150(10):1072-8. PubMed ID: 25103148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
